ArticleClinicoEconomics and outcomes research : CEOR2020

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.

Celine J Van De Laar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.